OracleBio will be attending the Annual Tumor Models Boston Summit, which takes place on the 18th – 20th July 2017.
OracleBio offers a range of digital pathology image analysis services to support pre-clinical and clinical oncology R&D. We have experience working with both xenograft and syngeneic tumour models, including working on immune checkpoint inhibitor studies in these models. For more information on how our services can support your research, please click here.
Returning for its 5th year, Tumor Models Boston 2017 will address the pre-clinical & clinical developments of the most promising therapies including targeted therapies, check-point inhibitors & CAR-T therapies and how these findings can be utilized to bridge the gap between pre-clinical and clinical studies. To find out more about the event, please click here.
If you would like to learn more about OracleBio’s services, or wish to arrange a time to speak with Business Development Manager Matt Gaffney during the conference, please contact us.
To keep up to date with all OracleBio news and events, please follow us on LinkedIn by clicking the button below: